Graduale Albiense.

F. 1v Labyrinthe contenant des vers latins commençant par les lettres O et T. F. 2 Prosa s. Salvii : « Alleluia regi... » F. 2v Prosa in Penthecosten : « Sancti Spiritus adsit nobis gratia... » F. 3 Antiennes diverses. F. 4v-146v Graduel, avec plusieurs versets alléluiatiques à chaque messe, proses et pièces gallicanes et wisigothiques : — Litanies d'Albi (67) ; — ste Cécile (121) ; — Messes diverses (135v) ; — Preces mortuorum (138) ; — Antiennes diverses (139-145v) ; — s. Sauve (145) ; — Toussaint (145v). F. 147 Versi de tonis : « Pange, Camena, tuis... » ; — Tonaire : « Diximus enim octo... » F. 148-153v et 155 : « Nonenoe ane » et formules complètes des huit tons.

Pontificale Christiani, archiepiscopi Moguntini.

F. 1 Oraison « Panis sancte, panis vive, panis pulcher... » F. 1v Ordo missae (Martène, De ant. eccl. rit., I, 600). F. 16-112 Pontifical : — Benedictio lapidis itinerarii (89v), — olei (90). F. 112v Bénédictions épiscopales.

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project.

PURPOSE: The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. METHODS: Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for FISH testing. Testing was performed in 16 participating centers, using the same protocol after passing external quality assessment. RESULTS: Positive ALK IHC staining was present in 80 patients (prevalence of 6.2%; 95% CI, 4.9% to 7.6%). Of these, 28 patients were ALK FISH positive, corresponding to a lower bound for the prevalence of FISH positivity of 2.2%. FISH specificity was 100%, and FISH sensitivity was 35.0% (95% CI, 24.7% to 46.5%), with a sensitivity value of 81.3% (95% CI, 63.6% to 92.8%) for IHC 2+/3+ patients. The hazard of death for FISH-positive patients was lower than for IHC-negative patients (P = .022). Multivariable models, adjusted for patient, tumor, and treatment characteristics, and matched cohort analysis confirmed that ALK FISH positivity is a predictor for better overall survival (OS). CONCLUSION: In this large cohort of surgically resected lung adenocarcinomas, the prevalence of ALK positivity was 6.2% using IHC and at least 2.2% using FISH. A screening strategy based on IHC or H-score could be envisaged. ALK positivity (by either IHC or FISH) was related to better OS.

1.° Martyrologium Usuardi : nonulla sub finem desiderantur. — 2.° Necrologium abbatiae Moyssiacensis.

Colbertinus

1.° Vita sancti Ysarni, Abbatis monasterii sancti Victoris Massiliensis. — 2.° Expositio fidei à Leone Papa I. conscripta. — 3.° Sancti Augustini epistola ad Volusianum.

Petavianus

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

PURPOSE: Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using a time-to-event approach with relapse, re-treatment, and death commonly used as the events. We evaluated the timing and type of events in newly diagnosed DLBCL and compared patient outcome with reference population data. PATIENTS AND METHODS: Patients with newly diagnosed DLBCL treated with immunochemotherapy were prospectively enrolled onto the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource (MER) and the North Central Cancer Treatment Group NCCTG-N0489 clinical trial from 2002 to 2009. Patient outcomes were evaluated at diagnosis and in the subsets of patients achieving event-free status at 12 months (EFS12) and 24 months (EFS24) from diagnosis. Overall survival was compared with age- and sex-matched population data. Results were replicated in an external validation cohort from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Lymphome Non Hodgkinien 2003 (LNH2003) program and a registry based in Lyon, France. RESULTS: In all, 767 patients with newly diagnosed DLBCL who had a median age of 63 years were enrolled onto the MER and NCCTG studies. At a median follow-up of 60 months (range, 8 to 116 months), 299 patients had an event and 210 patients had died. Patients achieving EFS24 had an overall survival equivalent to that of the age- and sex-matched general population (standardized mortality ratio [SMR], 1.18; P = .25). This result was confirmed in 820 patients from the GELA study and registry in Lyon (SMR, 1.09; P = .71). Simulation studies showed that EFS24 has comparable power to continuous EFS when evaluating clinical trials in DLBCL. CONCLUSION: Patients with DLBCL who achieve EFS24 have a subsequent overall survival equivalent to that of the age- and sex-matched general population. EFS24 will be useful in patient counseling and should be considered as an end point for future studies of newly diagnosed DLBCL.

Marci Tullii Ciceronis somnium Scipionis : accedunt Macrobii commentariorum libri duo.

Mazarinaeus

1.° M. T. Ciceronis ad Caium Trebatium, Jurisconsultum, topica : passim inter lineas glossae. — 2.° A. Manlii Severini Boëtii in Ciceronis topica commentariorum libri sex.

Colbertinus

1.° Q. Horatii Flacci carmina, ars poëtica et satyrae, cum glossis. — 2.° M. Annaei Lucani Pharsalia, sive de bello civili libri decem : initium et finis desiderantur.

Colbertinus

Marii Servii Honorati commentarii in nonum, decimum et duodecimum librum aeneïdos : initium et finis desiderantur.

Colbertinus

Las subvenciones, instrumento para la participación en salud

Boletín semanal para profesionales sanitarios de la Secretaría General de Salud Pública y Participación Social de la Consejería de Salud